Head-To-Head Survey: CollPlant Biotechnologies (NASDAQ:CLGN) vs. CureVac (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

Analyst Ratings

This is a summary of current ratings and recommmendations for CureVac and CollPlant Biotechnologies, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1	0	0	0	1.00
CollPlant Biotechnologies	1	1	0	0	1.50

CollPlant Biotechnologies has a consensus price target of $120.00, indicating a potential upside of 3,399.56%. Given CollPlant Biotechnologies’ stronger consensus rating and higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than CureVac.

Profitability

This table compares CureVac and CollPlant Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
CollPlant Biotechnologies	-678.37%	-298.21%	-167.83%

Institutional and Insider Ownership

17.3% of CureVac shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 2.1% of CureVac shares are held by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares CureVac and CollPlant Biotechnologies”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74 million	14.78	$175.50 million	$0.72	6.47
CollPlant Biotechnologies	$2.37 million	2.73	-$11.49 million	($13.59)	-0.25

CureVac has higher revenue and earnings than CollPlant Biotechnologies. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

CureVac has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500.

Summary

CureVac beats CollPlant Biotechnologies on 8 of the 12 factors compared between the two stocks.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.